John Maraganore Alnylam Pharmaceuticals, Inc. (ALNY) insider trading activity

John Maraganore is Chief Executive Officer of ALNYLAM PHARMACEUTICALS, INC.. Currently has a direct ownership of 227,663 shares of ALNY, which is worth approximately $57.1 Million. The most recent transaction as insider was on Dec 22, 2021, when has been sold 6,636 shares (Common Stock) at a price of $188.55 per share, resulting in proceeds of $1,251,218. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 228K

0% 3M change

0% 12M change

Total Value Held $57.1 Million

JOHN MARAGANORE Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 22 2021	SELL Payment of exercise price or tax liability	$1,251,218 $188.55 p/Share	6,636 Reduced 2.83%	227,663 Common Stock
Dec 21 2021	BUY Grant, award, or other acquisition	-	14,167 Added 5.7%	234,299 Common Stock
Dec 10 2021	BUY Exercise of conversion of derivative security	$465,265 $86.69 p/Share	5,367 Added 2.38%	220,132 Common Stock
Nov 12 2021	SELL Open market or private sale	$5,854,410 $172.3 p/Share	33,978 Reduced 13.66%	214,765 Common Stock
Nov 12 2021	BUY Exercise of conversion of derivative security	$241,244 $7.1 p/Share	33,978 Added 12.02%	248,743 Common Stock
Aug 13 2021	SELL Open market or private sale	$6,790,703 $199.85 p/Share	33,979 Reduced 13.66%	214,765 Common Stock
Aug 13 2021	BUY Exercise of conversion of derivative security	$241,251 $7.1 p/Share	33,979 Added 12.02%	248,744 Common Stock
May 13 2021	SELL Open market or private sale	$4,462,802 $131.34 p/Share	33,979 Reduced 13.66%	214,765 Common Stock
May 13 2021	BUY Exercise of conversion of derivative security	$241,251 $7.1 p/Share	33,979 Added 12.02%	248,744 Common Stock
Apr 20 2021	SELL Payment of exercise price or tax liability	$999,782 $133.18 p/Share	7,507 Reduced 3.38%	214,765 Common Stock
Apr 19 2021	BUY Grant, award, or other acquisition	-	16,236 Added 6.81%	222,272 Common Stock
Feb 25 2021	SELL Open market or private sale	$5,068,987 $149.18 p/Share	33,979 Reduced 14.16%	206,036 Common Stock
Feb 25 2021	BUY Exercise of conversion of derivative security	$241,251 $7.1 p/Share	33,979 Added 12.4%	240,015 Common Stock
Feb 12 2021	SELL Payment of exercise price or tax liability	$880,554 $153.97 p/Share	5,719 Reduced 2.7%	206,036 Common Stock
Feb 11 2021	BUY Grant, award, or other acquisition	-	14,166 Added 6.27%	211,755 Common Stock
Nov 19 2020	SELL Open market or private sale	$4,345,625 $125.0 p/Share	34,765 Reduced 14.96%	197,589 Common Stock
Nov 19 2020	BUY Exercise of conversion of derivative security	$317,752 $9.14 p/Share	34,765 Added 13.01%	232,354 Common Stock

Also insider at

AGIO

AGIOS PHARMACEUTICALS, INC. Healthcare

Director

BEAM

Beam Therapeutics Inc. Healthcare

KYMR

Kymera Therapeutics, Inc. Healthcare

DNAC

Social Capital Suvretta Holdings Corp. III

Director

John Maraganore

Chief Executive Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALNY shares.

Notify only if

Value

Insider Trading

Get notified when an Alnylam Pharmaceuticals, Inc. insider buys or sells ALNY shares.

Notify only if

Operation

Value

Type

News

Receive news related to ALNYLAM PHARMACEUTICALS, INC.

Track Activities on ALNY

Account